FDC Ltd Q2 Net Profit Rises to Rs 283.7 Million; Revenue at Rs 4.73 Billion

FDC Ltd Delivers Stable Q2 on Strong Domestic and Export Sales

FDC Ltd, known for its popular pharmaceutical and healthcare product portfolio, announced a strong set of financial results for Q2 FY2025-26. The company reported a consolidated net profit of Rs 283.7 million, underpinned by solid traction across both domestic formulations and international markets.

Consolidated revenue from operations stood at Rs 4.73 billion for the quarter, aided by consistent performance in its core therapeutic categories such as oral rehydration salts, ophthalmics, and anti-infectives. FDC continues to strengthen its R&D capabilities and expand its global footprint through strategic product launches.

Key Highlights

Consolidated revenue from operations: Rs 4.73 billion

Consolidated net profit: Rs 283.7 million (Q2 FY2025-26)

Steady growth in domestic formulations and export segments

Continued expansion in ophthalmic and oral rehydration markets

Focus on innovation, R&D investment, and geographic diversification

FDC’s operational strength and focus on innovation are expected to sustain its growth momentum in the coming quarters.

Sources: Company exchange filing (BSE), FDC Ltd corporate announcement.